Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics' GelVac™ Nasal Dry-Powder H5N1 Influenza Vaccine Shown to Be Safe in Early Stage Clinical Trial

PRWeb - October 2011

Nanotherapeutics, Inc. announced the successful completion of a Phase 1 clinical trial of GelVac? Nasal Dry-Powder H5N1 Influenza Vaccine. The trial assessed the safety of the novel intranasal dry-powder formulation vaccine for the H5N1 flu strain.

Full Article

Copyright 2015 NANOTHERAPEUTICS, INC.  All rights reserved.